{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:07:36Z","timestamp":1783436856822,"version":"3.54.6"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011769","name":"Scripps Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40259-024-00661-6","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:01:26Z","timestamp":1719280886000},"page":"527-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives"],"prefix":"10.1007","volume":"38","author":[{"given":"Amy L.","family":"Lightner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham M.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Betancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"23","key":"661_CR1","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"1","key":"661_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"issue":"9317","key":"661_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"2","key":"661_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323\u201333.","journal-title":"Gastroenterology"},{"issue":"3","key":"661_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357(3):228\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"661_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N Engl J Med. 2007;357(3):239\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"661_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology. 2004;126(2):402\u201313.","journal-title":"Gastroenterology"},{"issue":"12","key":"661_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829\u201338.","journal-title":"Ann Intern Med"},{"issue":"6","key":"661_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology"},{"issue":"2","key":"661_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289\u201397.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"661_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","volume":"89","author":"JD Feuerstein","year":"2014","unstructured":"Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553\u201363.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"661_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54 e42 (quiz e30).","journal-title":"Gastroenterology"},{"issue":"6","key":"661_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/gut.21.6.525","volume":"21","author":"G Hellers","year":"1980","unstructured":"Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn\u2019s disease. Gut. 1980;21(6):525\u20137.","journal-title":"Gut"},{"issue":"12","key":"661_CR14","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s10350-007-9006-5","volume":"50","author":"MS Kasparek","year":"2007","unstructured":"Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn\u2019s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50(12):2067\u201374.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"661_CR15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice C. AGA technical review on perianal Crohn\u2019s disease. Gastroenterology. 2003;125(5):1508\u201330.","journal-title":"Gastroenterology"},{"issue":"4","key":"661_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875\u201380.","journal-title":"Gastroenterology"},{"issue":"8","key":"661_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1463-1318.2008.01552.x","volume":"10","author":"CD Hannaway","year":"2008","unstructured":"Hannaway CD, Hull TL. Current considerations in the management of rectovaginal fistula from Crohn\u2019s disease. Colorectal Dis. 2008;10(8):747\u201355 (discussion 55\u20136).","journal-title":"Colorectal Dis"},{"issue":"2","key":"661_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/BF02562636","volume":"31","author":"AG Radcliffe","year":"1988","unstructured":"Radcliffe AG, Ritchie JK, Hawley PR, Lennard-Jones JE, Northover JM. Anovaginal and rectovaginal fistulas in Crohn\u2019s disease. Dis Colon Rectum. 1988;31(2):94\u20139.","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"661_CR19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","volume":"2","author":"BE Sands","year":"2004","unstructured":"Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912\u201320.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"661_CR20","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s10350-007-9057-7","volume":"50","author":"SM Andreani","year":"2007","unstructured":"Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn\u2019s disease. Dis Colon Rectum. 2007;50(12):2215\u201322.","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"661_CR21","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1007\/s10620-013-2830-7","volume":"58","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Zanotti C, Burgueno P, Vera I, Bermejo F, Marin-Jimenez I, et al. Health care costs of complex perianal fistula in Crohn\u2019s disease. Dig Dis Sci. 2013;58(12):3400\u20136.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"661_CR22","first-page":"33","volume":"30","author":"L Aguilera-Castro","year":"2017","unstructured":"Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn\u2019s disease. Ann Gastroenterol. 2017;30(1):33\u201344.","journal-title":"Ann Gastroenterol"},{"issue":"11","key":"661_CR23","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/MIB.0000000000000148","volume":"20","author":"I Molendijk","year":"2014","unstructured":"Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn\u2019s disease fistula. Inflamm Bowel Dis. 2014;20(11):2022\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"661_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"10","key":"661_CR25","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","volume":"14","author":"S Bonovas","year":"2016","unstructured":"Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385-97 e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"661_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/DCR.0b013e3181ce8b01","volume":"53","author":"A Soltani","year":"2010","unstructured":"Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn\u2019s fistula-in-ano. Dis Colon Rectum. 2010;53(4):486\u201395.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"661_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","volume":"9","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn\u2019s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9(2):98\u2013103.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"661_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s11605-010-1167-1","volume":"14","author":"G El-Gazzaz","year":"2010","unstructured":"El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and predictors of failure in women undergoing repair of Crohn\u2019s related rectovaginal fistula. J Gastrointest Surg. 2010;14(5):824\u20139.","journal-title":"J Gastrointest Surg"},{"issue":"12","key":"661_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/DCR.0b013e31823122b3","volume":"54","author":"SR Steele","year":"2011","unstructured":"Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD, Standards Practice Task Force of the American Society of C, and Rectal S. Practice parameters for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum. 2011;54(12):1465\u201374.","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"661_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/BF02560279","volume":"28","author":"BG Wolff","year":"1985","unstructured":"Wolff BG, Culp CE, Beart RW Jr, Ilstrup DM, Ready RL. Anorectal Crohn\u2019s disease. A long-term perspective. Dis Colon Rectum. 1985;28(10):709\u201311.","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"661_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpsurg.2020.100808","volume":"57","author":"AL Lightner","year":"2020","unstructured":"Lightner AL, Ashburn JH, Brar MS, Carvello M, Chandrasinghe P, van Overstraeten AB, et al. Fistulizing Crohn\u2019s disease. Curr Probl Surg. 2020;57(11): 100808.","journal-title":"Curr Probl Surg"},{"issue":"9","key":"661_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/ncb0901-778","volume":"3","author":"JG Toma","year":"2001","unstructured":"Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR, Miller FD. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001;3(9):778\u201384.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"661_CR33","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1634\/stemcells.2004-0013","volume":"22","author":"HS Wang","year":"2004","unstructured":"Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton\u2019s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330\u20137.","journal-title":"Stem Cells"},{"issue":"1","key":"661_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jcp.20636","volume":"208","author":"K Yoshimura","year":"2006","unstructured":"Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208(1):64\u201376.","journal-title":"J Cell Physiol"},{"issue":"9624","key":"661_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579\u201386.","journal-title":"Lancet"},{"issue":"8","key":"661_CR36","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467\u201375.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"661_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","volume":"5","author":"RH Lee","year":"2009","unstructured":"Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54\u201363.","journal-title":"Cell Stem Cell"},{"issue":"1\u20132","key":"661_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","volume":"227","author":"B Yamout","year":"2010","unstructured":"Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1\u20132):185\u20139.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"661_CR39","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","volume":"48","author":"D Garc\u00eda-Olmo","year":"2005","unstructured":"Garc\u00eda-Olmo D, Garc\u00eda-Arranz M, Herreros D, Pascual I, Peiro C, Rodr\u00edguez-Montes JA. A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416\u201323.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"661_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cellimm.2015.01.002","volume":"293","author":"T Gharibi","year":"2015","unstructured":"Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cell Immunol. 2015;293(2):113\u201321.","journal-title":"Cell Immunol"},{"issue":"14","key":"661_CR41","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1089\/scd.2013.0554","volume":"23","author":"EA Kimbrel","year":"2014","unstructured":"Kimbrel EA, Kouris NA, Yavanian GJ, Chu J, Qin Y, Chan A, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 2014;23(14):1611\u201324.","journal-title":"Stem Cells Dev."},{"key":"661_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113841","volume":"179","author":"AC Sebbagh","year":"2021","unstructured":"Sebbagh AC, Rosenbaum B, P\u00e9r\u00e9 G, Alric H, Berger A, Wilhelm C, et al. Regenerative medicine for digestive fistulae therapy: benefits, challenges and promises of stem\/stromal cells and emergent perspectives via their extracellular vesicles. Adv Drug Deliv Rev. 2021;179: 113841.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"661_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2249.2007.03422.x","volume":"149","author":"JM Ryan","year":"2007","unstructured":"Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp immunol. 2007;149(2):353\u201363.","journal-title":"Clin Exp immunol"},{"issue":"12","key":"661_CR44","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","volume":"103","author":"R Meisel","year":"2004","unstructured":"Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619\u201321.","journal-title":"Blood"},{"issue":"10","key":"661_CR45","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/stem.1483","volume":"31","author":"JA Horton","year":"2013","unstructured":"Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31(10):2231\u201341.","journal-title":"Stem Cells"},{"key":"661_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/583409","volume":"2014","author":"R Pezato","year":"2014","unstructured":"Pezato R, de Almeida DC, Bezerra TF, Silva Fde S, Perez-Novo C, Gregorio LC, et al. Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. Mediators Inflamm. 2014;2014: 583409.","journal-title":"Mediators Inflamm"},{"issue":"11","key":"661_CR47","first-page":"533","volume":"17","author":"AL Lightner","year":"2021","unstructured":"Lightner AL. Management of fistulas in patients with Crohn\u2019s disease. Gastroenterol Hepatol (NY). 2021;17(11):533\u20135.","journal-title":"Gastroenterol Hepatol (NY)."},{"issue":"5","key":"661_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00384-003-0490-3","volume":"18","author":"D Garc\u00eda-Olmo","year":"2003","unstructured":"Garc\u00eda-Olmo D, Garc\u00eda-Arranz M, Garc\u00eda LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn\u2019s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451\u20134.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"661_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13287-023-03331-6","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Jiang HY, Zhang YX, Jin HY, Fei BY, Jiang JL. Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials. Stem Cell Res Ther. 2023;14(1):103.","journal-title":"Stem Cell Res Ther"},{"issue":"10051","key":"661_CR50","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Panes","year":"2016","unstructured":"Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281\u201390.","journal-title":"Lancet"},{"issue":"5","key":"661_CR51","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","volume":"154","author":"J Panes","year":"2018","unstructured":"Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2018;154(5):1334-42 e4.","journal-title":"Gastroenterology"},{"key":"661_CR52","doi-asserted-by":"crossref","unstructured":"Panes J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F, et al. INSPECT: a retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing Crohn\u2019s disease treated in the ADMIRE-CD trial. Inflamm Bowel Dis. 2022.","DOI":"10.1093\/ibd\/izab361"},{"issue":"1","key":"661_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ecco-jcc\/jjz116","volume":"14","author":"MC Barnhoorn","year":"2020","unstructured":"Barnhoorn MC, Wasser M, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn\u2019s disease perianal fistulas. J Crohns Colitis. 2020;14(1):64\u201370.","journal-title":"J Crohns Colitis"},{"key":"661_CR54","doi-asserted-by":"crossref","unstructured":"Lightner AL, Reese J, Ream J, Nachand D, Jia X, Dadgar N, et al. A phase IB\/IIA study of ex vivo expanded allogeneic bone marrow derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn\u2019s disease. Dis Colon Rectum. 2023.","DOI":"10.1097\/DCR.0000000000002567"},{"key":"661_CR55","doi-asserted-by":"crossref","unstructured":"Lightner AL, Reese JS, Ream J, Nachand D, Dadgar N, Adams A, VanDenBossche A, Pineiro AO, Hull T. A phase IB\/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn's disease. Surgery. 2024;175(2):242\u20139.","DOI":"10.1016\/j.surg.2023.07.020"},{"key":"661_CR56","doi-asserted-by":"crossref","unstructured":"Lightner AL, Otero-Pineiro A, Reese J, Ream J, Nachand D, Adams AC, VanDenBossche A, Kurowski JA. A phase I study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of pediatric perianal fistulizing Crohn's disease. Inflamm Bowel Dis. 2023;29(12):1912\u20139.","DOI":"10.1093\/ibd\/izad100"},{"issue":"3","key":"661_CR57","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2008.11.041","volume":"136","author":"MA Gonzalez","year":"2009","unstructured":"Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978\u201389.","journal-title":"Gastroenterology"},{"issue":"7","key":"661_CR58","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/gut.2008.168534","volume":"58","author":"E Gonzalez-Rey","year":"2009","unstructured":"Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929\u201339.","journal-title":"Gut"},{"issue":"1","key":"661_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15283\/ijsc17074","volume":"11","author":"F de la Portilla","year":"2018","unstructured":"de la Portilla F, Yuste Y, Pereira S, Olano C, Maestre MV, Padillo FJ. Local mesenchymal stem cell therapy in experimentally induced colitis in the rat. Int J Stem Cells. 2018;11(1):39\u201347.","journal-title":"Int J Stem Cells."},{"issue":"48","key":"661_CR60","doi-asserted-by":"publisher","first-page":"18228","DOI":"10.3748\/wjg.v20.i48.18228","volume":"20","author":"C Goncalves Fda","year":"2014","unstructured":"Goncalves Fda C, Schneider N, Pinto FO, Meyer FS, Visioli F, Pfaffenseller B, et al. Intravenous vs intraperitoneal mesenchymal stem cells administration: what is the best route for treating experimental colitis? World J Gastroenterol. 2014;20(48):18228\u201339.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"661_CR61","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1007\/s10620-012-2290-5","volume":"57","author":"XW He","year":"2012","unstructured":"He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57(12):3136\u201344.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"661_CR62","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3727\/096368910X557245","volume":"20","author":"L Liang","year":"2011","unstructured":"Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M, et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant. 2011;20(9):1395\u2013408.","journal-title":"Cell Transplant"},{"issue":"5","key":"661_CR63","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/scd.2008.0253","volume":"18","author":"UM Fischer","year":"2009","unstructured":"Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683\u201392.","journal-title":"Stem Cells Dev."},{"issue":"3","key":"661_CR64","first-page":"619","volume":"32","author":"ZQ Fu","year":"2018","unstructured":"Fu ZQ, Zhou Q, Zhu S, Liu W. Anti-tumor mechanism of IL-21 used alone and in combination with 5-fluorouracil in vitro on human gastric cancer cells. J Biol Regul Homeost Agents. 2018;32(3):619\u201325.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"661_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jcyt.2014.12.004","volume":"17","author":"T Makela","year":"2015","unstructured":"Makela T, Takalo R, Arvola O, Haapanen H, Yannopoulos F, Blanco R, et al. Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy. 2015;17(4):392\u2013402.","journal-title":"Cytotherapy"},{"issue":"12","key":"661_CR66","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/gut.2010.215152","volume":"59","author":"M Duijvestein","year":"2010","unstructured":"Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study. Gut. 2010;59(12):1662\u20139.","journal-title":"Gut"},{"issue":"1","key":"661_CR67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","volume":"12","author":"GM Forbes","year":"2014","unstructured":"Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn\u2019s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12(1):64\u201371.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"661_CR68","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3892\/etm.2016.3724","volume":"12","author":"J Hu","year":"2016","unstructured":"Hu J, Zhao G, Zhang L, Qiao C, Di A, Gao H, Xu H. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med. 2016;12(5):2983\u20139.","journal-title":"Exp Ther Med"},{"key":"661_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","volume":"7","author":"J Leibacher","year":"2016","unstructured":"Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells. Stem Cell Res Ther. 2016;7:7.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"661_CR70","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/codi.16239","volume":"24","author":"AL Lightner","year":"2022","unstructured":"Lightner AL, Dadgar N, Matyas C, Elliott K, Fulmer C, Khaitan N, et al. A phase IB\/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. Colorectal Dis. 2022;24(11):1358\u201370.","journal-title":"Colorectal Dis"},{"issue":"8","key":"661_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/bjs\/znac078","volume":"109","author":"AL Lightner","year":"2022","unstructured":"Lightner AL, Ream J, Nachand D, Fulmer C, Regueiro M, Steele SR. Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn\u2019s colitis: preliminary phase IB\/IIA study. Br J Surg. 2022;109(8):653\u20135.","journal-title":"Br J Surg"},{"issue":"2","key":"661_CR72","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/stcltm\/szad003","volume":"12","author":"M Anbazhagan","year":"2023","unstructured":"Anbazhagan M, Geem D, Venkateswaran S, Pelia R, Kolachala VL, Dodd A, et al. Characterization of intestinal mesenchymal stromal cells from patients with inflammatory bowel disease for autologous cell therapy. Stem Cells Transl Med. 2023;12(2):112\u201322.","journal-title":"Stem Cells Transl Med"},{"key":"661_CR73","doi-asserted-by":"publisher","first-page":"5356760","DOI":"10.1155\/2017\/5356760","volume":"2017","author":"F Mao","year":"2017","unstructured":"Mao F, Wu Y, Tang X, Kang J, Zhang B, Yan Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice. Biomed Res Int. 2017;2017:5356760.","journal-title":"Biomed Res Int"},{"key":"661_CR74","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Ferrer M, Amaro-Prellezo E, Dorronsoro A, S\u00e1nchez-S\u00e1nchez R, Vicente \u00c1, Cos\u00edn-Roger J, et al. HIF-overexpression and pro-inflammatory priming in human mesenchymal stromal cells improves the healing properties of extracellular vesicles in experimental Crohn\u2019s disease. Int J Mol Sci. 2021;22(20).","DOI":"10.3390\/ijms222011269"},{"issue":"4","key":"661_CR75","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/jgh.16110","volume":"38","author":"H Pak","year":"2023","unstructured":"Pak H, Hadizadeh A, Heirani-Tabasi A, Soleimani M, Asbagh RA, Fazeli MS, et al. Safety and efficacy of injection of human placenta mesenchymal stem cells derived exosomes for treatment of complex perianal fistula in non-Crohn\u2019s cases: clinical trial phase I. J Gastroenterol Hepatol. 2023;38(4):539\u201347.","journal-title":"J Gastroenterol Hepatol"},{"key":"661_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716499","volume":"12","author":"J Jacobse","year":"2021","unstructured":"Jacobse J, Li J, Rings E, Samsom JN, Goettel JA. Intestinal regulatory T cells as specialized tissue-restricted immune cells in intestinal immune homeostasis and disease. Front Immunol. 2021;12: 716499.","journal-title":"Front Immunol"},{"issue":"5","key":"661_CR77","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/gutjnl-2019-319850","volume":"69","author":"JN Clough","year":"2020","unstructured":"Clough JN, Omer OS, Tasker S, Lord GM, Irving PM. Regulatory T-cell therapy in Crohn\u2019s disease: challenges and advances. Gut. 2020;69(5):942\u201352.","journal-title":"Gut"},{"issue":"5","key":"661_CR78","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00384-003-0490-3","volume":"18","author":"D Garcia-Olmo","year":"2003","unstructured":"Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn\u2019s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451\u20134.","journal-title":"Int J Colorectal Dis"},{"issue":"7","key":"661_CR79","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","volume":"48","author":"D Garcia-Olmo","year":"2005","unstructured":"Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416\u201323.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"661_CR80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/DCR.0b013e3181973487","volume":"52","author":"D Garcia-Olmo","year":"2009","unstructured":"Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79\u201386.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"661_CR81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3727\/096368912X656045","volume":"22","author":"YB Cho","year":"2013","unstructured":"Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn\u2019s fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279\u201385.","journal-title":"Cell Transplant"},{"issue":"11","key":"661_CR82","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/stem.1357","volume":"31","author":"WY Lee","year":"2013","unstructured":"Lee WY, Park KJ, Cho YB, Yoon SN, Song KH, Kim DS, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn\u2019s fistula. Stem Cells. 2013;31(11):2575\u201381.","journal-title":"Stem Cells"},{"issue":"5","key":"661_CR83","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5966\/sctm.2014-0199","volume":"4","author":"YB Cho","year":"2015","unstructured":"Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn\u2019s fistula. Stem Cells Transl Med. 2015;4(5):532\u20137.","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"661_CR84","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/gut.2010.214841","volume":"60","author":"R Ciccocioppo","year":"2011","unstructured":"Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn\u2019s disease. Gut. 2011;60(6):788\u201398.","journal-title":"Gut"},{"issue":"3","key":"661_CR85","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00384-012-1581-9","volume":"28","author":"F de la Portilla","year":"2013","unstructured":"de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn\u2019s disease: results from a multicenter phase I\/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313\u201323.","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"661_CR86","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1053\/j.gastro.2015.06.014","volume":"149","author":"I Molendijk","year":"2015","unstructured":"Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2015;149(4):918-27 e6.","journal-title":"Gastroenterology"},{"issue":"1","key":"661_CR87","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2017.04.001","volume":"153","author":"AB Dietz","year":"2017","unstructured":"Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology. 2017;153(1):59-62 e2.","journal-title":"Gastroenterology"},{"key":"661_CR88","doi-asserted-by":"crossref","unstructured":"Barnhoorn MC, Wasser M, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn\u2019s disease perianal fistulas. J Crohns Colitis. 2019.","DOI":"10.1093\/ecco-jcc\/jjz116"},{"issue":"10","key":"661_CR89","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/DCR.0000000000002567","volume":"66","author":"AL Lightner","year":"2023","unstructured":"Lightner AL, Reese J, Ream J, Nachand D, Jia X, Dadgar N, et al. A phase IB\/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn\u2019s disease. Dis Colon Rectum. 2023;66(10):1359\u201372.","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"661_CR90","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ecco-jcc\/jjac172","volume":"17","author":"AL Lightner","year":"2023","unstructured":"Lightner AL, Reese J, Ream J, Nachand D, Jia X, Pineiro AO, et al. A phase IB\/IIA study of allogeneic, bone marrow-derived, mesenchymal stem cells for the treatment of refractory ileal-anal anastomosis and peripouch fistulas in the setting of Crohn\u2019s disease of the pouch. J Crohns Colitis. 2023;17(4):480\u20138.","journal-title":"J Crohns Colitis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00661-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T03:27:07Z","timestamp":1721014027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00661-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00661-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"14 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ALL: Consulting: Boomerang Medical; AB: Founder and Chief Scientific Officer of Vitabolus.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to writing and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}